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Signal transducer and activators of transcription (STAT)1 and STAT3 cross-regulate their activity
downstream of gp130 cytokines, and eliminating STAT3 leads to IFN-c-like responses to IL-6 corre-
lating with prolonged STAT1 phosphorylation. Here we demonstrate that the increased gp130-med-
iated induction of the IFN-c-responsive interferon regulatory factor 1 gene observed in STAT3/
cells correlates with prolonged STAT1 binding to its promoter. Intriguingly, gp130-mediated induc-
tion of the immediate early genes FBJ osteosarcoma oncogene and early growth response 1 is also
prolonged in STAT3/ cells, with STAT1 binding to their promoters. Thus the abrogation of STAT3
expression, perturbing the signaling balance, directs the STAT1 oncosuppressor to transcribe new
target genes, known to drive mitogen responses and tumor transformation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Signal transducer and activators of transcription (STAT) factors
mediate the signaling downstream of cytokine and growth factor
receptors, becoming activated via tyrosine-phosphorylation to reg-
ulate gene expression [1]. The two family members STAT1 and
STAT3 have remarkably distinct target genes in vivo, despite exhib-
iting virtually indistinguishable DNA binding speciﬁcity and afﬁn-
ity in vitro. Accordingly, these two factors often display opposite
functions in biologically relevant processes such as inﬂammation,
proliferation/survival and tumor onset and growth [2,3]. For exam-
ple, STAT3 is considered an oncogene and is constitutively active in
a high number of primary tumors of various origin, where it pro-
motes proliferation, survival and tissue invasion, while STAT1 ex-
erts mainly anti-oncogenic functions both by promoting growth
arrest and cell death and via the activation of the immune systemchemical Societies. Published by E
tors of transcription; MAPK,
M; SRE, serum response
plex factor; SIE, sis-inducible
pidermal growth factor; GAS,
growth response 1; Fos, FBJ
ctor 1; Elk1, member of ETS
ia Ribes 5, 10010 Colleretto[3,4]. STAT3 has recently emerged as a key player in holding the
balance not only between the reciprocal STAT3 versus STAT1 acti-
vation levels but also between the STAT versus the mitogen-acti-
vated protein kinase (MAPK) branches of cytokine signaling
[2,5,6]. Indeed, STAT3/ ﬁbroblasts display an IFN-c-like response
to IL-6, including prolonged STAT1 activation, induction of IFN-c
target genes and antiviral activity [5,6]. Likewise, MAPK activation
downstream of several IL-6 family cytokines, sharing the gp130
receptor subunit, is prolonged in the absence of STAT3 signaling,
both in vitro and in vivo [7–9].
Immediate early genes are rapidly induced upon growth stimu-
lation mediated by serum, growth factors and mitogens, which all
lead to the activation of MAPK pathways [10], and are mostly regu-
lated via serum response elements (SREs) on their promoter re-
gions. The SRE, together with ﬂanking DNA sequences, represents
the site of assembly of a ternary complex including the serum re-
sponse factor (SRF), ternary complex factor (TCF)/member of ETS
oncogene family (Elk1) and other transcription factors [11–13].
Phosphorylation of Elk1 by MAPKs promotes complex formation
and transcription. The promoter of the FBJ osteosarcoma oncogene
(Fos) carries a well characterized SRE, essential for mitogen-medi-
ated transcriptional activation [12], as well as a platelet-derived
growth factor (PDGF)-responsive sis-inducible element (SIE) [14],
which mediates STAT3-dependent transcription and contributes
to full promoter activity downstream of gp130 cytokines [12,15].
Another immediate early gene co-regulatedwith Fos during growth
and differentiation is the epidermal growth factor (EGF)-responsivelsevier B.V. All rights reserved.
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have been described on the Egr1 promoter region, but no SIE-like
element. We have recently identiﬁed a STAT3 binding site (BS) con-
served on both the mouse and human Egr1 promoters [17], which
we show here to be functional. We observe that, similar to the
IFN-c-responsive genes, both Fos and Egr1 display prolonged tran-
scriptional activation in STAT3/ mouse embryonic ﬁbroblasts
(MEFs), and we investigate whether this is due to prolonged activa-
tion of either MAPKs or STAT1.
2. Materials and methods
2.1. Cell lines and treatments
STAT3+/+ and STAT3/ immortalized MEFs [5] were grown as
previously described [18]. Cells were treated with recombinant
oncostatin M (OSM) (R&D Systems, 20 ng/ml), recombinant murine
IFN-c (Peprotech, 100 lg/ml) or recombinant EGF (Sigma–Aldrich,
10 ng/ml) for different time lengths. The inhibitors PD98059 (MEK)
and P6 (JAKs) (Calbiochem), were used at a ﬁnal concentration of
25 and 1 lM, respectively, 1 h before cytokine stimulation, and
maintained throughout the experiment.
2.2. Western blot analysis
Total protein extracts and SDS/PAGE fractionation were per-
formed as previously described [18]. The following antibodies were
used: anti-total and phospho-STAT3 (Tyr705), anti-total and phos-
pho-STAT1 (Tyr701), anti-p44/42 MAPK (Erk1/2) and phospho-
p44/42 MAPK (Tyr202/Tyr204) (Cell Signaling Technology), anti-
Actin (Santa Cruz Biotechnology).
2.3. RNA extraction, retro-transcription and quantitative real-time PCR
(qRT-PCR)
Total RNA, retro-transcription and qRT-PCRs were performed as
previously described [17]. qRT-PCRs were performed using the
Universal Probe Library system (Roche). Primer sequences and
probe numbers are reported in Supplementary Table 1. ResultsFig. 1. Prolonged induction of Fos, Egr1 and Irf1 mRNAs in OSM-treated STAT3/ MEFs.
either untreated or stimulated with OSM (A) or IFN-c (B) for the indicated times. Fos, Egr1
results are shown as means ± S.E.M. of two independent experiments performed in tripwere analyzed with the 2DDCt method using the 18S rRNA pre-
developed TaqMan assay (Applied Biosystems) as an internal
control.
2.4. Chromatin immunoprecipitation (ChIP) assays
STAT3+/+ and STAT3/MEFs were treated or not with OSM, IFN-
c or EGF for the indicated times. ChIP assays were performed as
previously described [18]. Immunoprecipitations were performed
by incubating the sheared chromatin overnight with the following
antibodies: anti-acetyl-histone H3 (Upstate Cell Signaling Solu-
tions, 2 lg), anti-STAT3 (R&D Systems, 5 ll), anti-STAT1 (C-termi-
nus) (BD Transduction Laboratories, 2 lg), anti-phospho-Elk1
(Santa Cruz Biotechnology, 2 lg) or negative control IgG
(Sigma–Aldrich, 2 lg). Primer sequences used for the PCR reactions
are reported in Supplementary Table 2. In vivo binding values were
obtained by subtracting the background signal (IgG) from the
speciﬁc signal (STAT3 or STAT1) followed by normalization to
chromatin content (TI) using the following formula: [(STAT3 or
STAT1)  (IgG)]/TI. Negative values (STAT3 or STAT1 signal lower
than IgG signal) were arbitrarily set as zero and marked with an
asterisk.
2.5. Electrophoretic mobility shift assay (EMSA)
EMSA experiments were performed as previously described
[17], using the following consensus SRE sequences: Sense 50-CAG
GATGTCCATATTAGGACA-30; Antisense 50-CAGA TGTCCTA ATATG
GACAT-30. A 10-fold molar excess of cold double stranded
oligonucleotide was added as competitor prior to incubating with
the labeled probe.
3. Results
3.1. OSM elicits prolonged induction of the Fos and Egr1 mRNAs in the
absence of STAT3
Similarly to what we have previously shown for IL-6 [5], OSM,
another gp130 cytokine, could trigger prolonged induction of theTotal RNA was extracted from STAT3+/+ (white bars) or STAT3/ (black bars) MEFs
and Irf1 mRNAs were measured by qRT-PCR. Expression was normalized to 18S, and
licate (⁄P < 0.05; ⁄⁄P < 0.01).
Fig. 2. Prolonged STAT1 and MAP kinase activation by OSM in STAT3/ MEFs.
STAT3+/+ and STAT3/ MEFs were treated with OSM (20 ng/ml, A) or IFN-c (100 lg/
ml, B) for the indicated times. Phospho-STAT3, phospho-STAT1, phospho-Erk1/2
and total STAT3, STAT1, Erk1/2 were measured by immunoblot.
Fig. 3. Sustained induction of Fos, Egr1 and Irf1 mRNAs is independent of MAP kinase acti
MEK inhibitor PD98059 and stimulated or not with OSM for the indicated times. Total m
qRT-PCR. Results are shown as mean ± S.E.M. of three independent experiments. Aster
PD98059 treatment in mediating MAP kinase inhibition at short (0.5 h) and long (6 h
immunoblot.
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STAT3-deﬁcient MEFs (Fig. 1A). Intriguingly, we noticed that the
immediate early genes Fos and Egr1, which are not IFN-c-respon-
sive genes, displayed a similar behavior, with enhanced expression
in STAT3/ cells treated for 3 h with IL-6 or OSM [17]. We there-
fore compared the induction kinetics of Irf1, Fos and Egr1 mRNAs
in both STAT3+/+ and STAT3/ MEFs upon either IFN-c or OSM
stimulation. IFN-c could weakly and only transiently induce Fos
and Egr1 in cells of both genotypes (Fig. 1B), while as expected
Irf1 induction was robust and sustained. OSM could trigger stron-
ger and less transient Fos and Egr1 induction in the wild type
MEFs, and this was signiﬁcantly prolonged (up to 24 h) in the ab-
sence of STAT3 (Fig. 1A). Thus, similar to what observed for Irf1
and the canonical IFN-c-responsive genes, also the induction of
the Fos and Egr1 immediate early genes is signiﬁcantly prolonged
in the absence of STAT3 in a dose-dependent fashion (Supplemen-
tary Fig. 1A).
3.2. Prolonged activation of both STAT1 and MAPK upon OSM
stimulation in STAT3/ MEFs
As in the case of IL-6 [5], OSM treatment elicits prolonged
STAT1 phosphorylation in STAT3/ MEFs (Fig. 2A), even at low
doses (Supplementary Fig. 1B). OSM-treated STAT3/ cells also
displayed sustained activation of the Ras-MAPK pathway, as
showed by the prolonged phosphorylation of Erk1/2 (Fig. 2A),
while neither STAT1 nor Erk1/2 activation were affected down-
stream of IFN-c (Fig. 2B).
3.3. Sustained induction of the Fos and Egr1 mRNAs is independent of
MAPK activity
To test whether the prolonged Fos and Egr1 induction observed
in the STAT3/ MEFs could be a consequence of the sustainedvity. (A) STAT3+/+ (white bars) and STAT3/ (black bars) MEFs were treated with the
RNA was extracted and the expression levels of Fos, Egr1 and Irf1 were measured by
isks indicate statistically signiﬁcant differences (P < 0.01). (B) The effectiveness of
) times of OSM treatment was assessed by measuring Erk1/2 phosphorylation by
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and STAT3/ MEFs with OSM for 30 min, 3 or 6 h in the presence
or absence of the MEK inhibitor PD98059 (Fig. 3A). MAPK inhibi-
tion reduced by about 10-fold Fos and Egr1 induction at 30 min
in cells of both genotypes. In contrast, only a partial reduction
was observed in the STAT3/ MEFs at 3 h and none at 6 h
(Fig. 3B). As expected, Irf1 induction was never affected (Fig. 3A),
in agreement with its known STAT-dependent activation. These
data conﬁrm the pivotal role of the MAPK pathway in the early
and transient activation of Fos and Egr1 by gp130 cytokines while
supporting an additional role for STAT3, since Fos and Egr1 induc-
tion was signiﬁcantly reduced at 30 min in its absence, particularly
upon Erk inhibition (Fig. 3A). Noteworthy, MAPK inhibition did not
affect Fos and Egr1 transcription at 6 h of stimulation in the
STAT3/ cells even though at this time point the pathway is still
active, as shown by Erk1/2 phosphorylation (Fig. 2) and by the
binding of phospho-Elk1 to the SRE sites on the Fos and Egr1 pro-
moters detected by chromatin immunoprecipitation (ChIP) analy-
sis (Supplementary Fig. 2A). Accordingly, in vitro SRE bindingFig. 4. In vivo binding of STAT3 and STAT1 on the Fos, Egr1 and Irf1 promoters. STAT3 (
Chromatin was prepared from STAT3+/+ (white bars) and STAT3/ (black bars) MEFs, ei
were performed with antibodies against acetylated-histone-H3 as a positive control, STAT
control (T.I.). PCR products (Supplementary Fig. 3) were analyzed and quantiﬁed as pr
experiments.activity was also unaffected (Supplementary Fig. 2B). Thus, even
though the SRE complex including pElk1 is bound to the Fos and
Egr1 promoters at 6 h of OSM treatment in the STAT3/ cells, at
this time point it does not appear to be engaged in their transcrip-
tional activation, suggesting that some other factor(s) must be
involved.
3.4. STAT1 can bind to the Fos and Egr1 promoters only in the absence
of STAT3
In order to assess whether STAT1, whose phosphorylation is
prolonged in the STAT3/ cells, may be directly responsible for
the sustained induction of the Fos, Egr1 and Irf1 mRNAs, we
decided to assess in vivo STAT1/3 binding to the newly identiﬁed
Egr1 STAT3 BS [17], the Fos SIE and the Irf1 gamma interferon acti-
vation sequence (GAS) elements [15,19]. Chromatin was prepared
from STAT3+/+ and STAT3/ MEFs treated or not with OSM or
IFN-c and subjected to immunoprecipitation with anti-STAT3 or
STAT1 antibodies (Fig. 4 and Supplementary Fig. 3). OSM treatmentA) and STAT1 (B) in vivo binding was assessed by chromatin immunoprecipitation.
ther unstimulated or treated with OSM or IFN-c (0.5 or 6 h). Immunoprecipitations
3, STAT1 or control IgG. Non-immunoprecipitated chromatin was used as total input
eviously described [17]. Results are shown as mean ± S.E.M. of three independent
D. Schiavone et al. / FEBS Letters 585 (2011) 2455–2460 2459at 30 min, but not at 6 h, elicited strong STAT3 binding to all three
promoters, suggesting that indeed STAT3 participates in the con-
trol of their early transcriptional induction (Fig. 4A, top). No signal
was of course detected in the STAT3/ MEFs. In contrast, at 30 min
IFN-c triggered either no (Egr1) or only very minor (Fos and Irf1)
STAT3 binding, which was then signiﬁcantly increased at 6 h only
on the Irf1 promoter (Fig. 4A, bottom). These observations corre-
late well with the induction kinetics of the respective mRNAs.
As expected, STAT1 was able to efﬁciently bind to the Irf1 GAS
element both 30 min and 6 h after IFN-c treatment, irrespective
of STAT3 status. In contrast, OSM triggered STAT1 binding only
at 30 min in the wild type cells, but also after 6 h in the
STAT3/ cells (Fig. 4B), in agreement with the mRNA induction
kinetics. Although STAT1 could never bind efﬁciently to the Fos
and Egr1 promoters in wild-type MEFs, strong STAT1 binding
was detected in the STAT3/ cells upon 6 h, but not 30 min, of
OSM stimulation (Fig. 4B, top). This suggests that phosphorylated
STAT1 is normally unable to bind to the Fos and Egr1 promoters
but acquires this ability in the absence of STAT3. Accordingly,
prolonged induction of the Fos and Egr1 mRNAs in the absence
of STAT3 is completely ablated by treatment with the JAK inhib-
itor P6, which abolishes STAT1 phosphorylation (Supplementary
Fig. 4). Of note STAT5, the other OSM-activated STAT factor, could
not be involved in this phenomenon since its phosphorylation
is only transient in both the STAT3/ and STAT3+/+ MEFs (data
not shown).
4. Discussion
Cross-talk between signaling pathways determines how a cell
integrates the environmental signals received, ultimately translat-
ing them in transcriptional regulation of speciﬁc sets of genes.
Interference with signaling elements is thus likely to perturb the
equilibrium, leading to often unpredictable outcomes. We have
previously shown that STAT3 can shape the responses to gp130
cytokines, affecting the duration of STAT1 activation via a mecha-
nism requiring STAT3-dependent de novo protein synthesis [5,6].
Accordingly, in the absence of STAT3, STAT1 activation was pro-
longed, resulting in IL-6 activating a set of IFN-c-responsive genes
[5]. Here we demonstrate that STAT1 binding to the Irf1 promoter
is indeed prolonged upon treatment with the gp130 cytokine OSM
in the absence of STAT3, consistent with STAT1-mediated tran-
scriptional activation.
The ﬁnding that the mRNAs for the immediate early genes Fos
and Egr1 behave similarly to Irf1 in the STAT3/ MEFs prompted
us to assess whether STAT1 played a role also in this case or
whether this phenomenon was due to the prolonged activation
of the MAPK pathway, the main recognized player in the induction
of the Fos and Egr1 genes. Surprisingly, our results show that nei-
ther MAPK activity nor SRE binding by phospho-Elk1 are appar-
ently involved in the late induction of the Fos and Egr1 genes,
which was not abolished by the MEK inhibitor PD98059. Lack of
Elk-1-mediated transcription might be due to the absence of some
other essential co-factor. In contrast, the observation that under
the same conditions both the Fos and Egr1 promoters are occupied
by active STAT1 and that inhibition of its phosphorylation abol-
ishes their prolonged induction supports the idea that it is indeed
STAT1, abnormally activated in the absence of STAT3, to mediate
transcriptional induction of their genes. Intriguingly STAT1, which
was previously shown to be unable to bind to the Fos promoter
[15], does not appear to simply replace STAT3. Indeed, despite
higher tyrosine-phosphorylation upon 30 min than 6 h of OSM
stimulation, STAT1 binds efﬁciently to the Fos and Egr1 promoters
in the STAT3/ cells only at the later time point, correlating well
with their prolonged transcriptional activation. In the wild typecells in contrast, STAT3 binds efﬁciently upon 30 min, but not
6 h, of OSM treatment. These differential binding abilities may be
due to differential requirement for cooperative binding with spe-
ciﬁc factors/co-factors, and/or for further post-transcriptional
modiﬁcation(s). Additionally, STAT1 may be able to bind and acti-
vate transcription even when chromatin is not in an open confor-
mation, due to its ability to induce/maintain an open chromatin
structure [20]. Our data may represent a starting point to investi-
gate the rule(s) dictating the in vivo binding speciﬁcity of the
two factors.
Our results clearly demonstrate that the elimination of a spe-
ciﬁc player – STAT3 – in a complex signaling pathway may lead
to non-linear secondary effects, underlining the caution with
which the results of gene inactivation experiments should be inter-
preted and therapeutic strategies based on the interference with
speciﬁc signaling steps designed.
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